FDA Grants Orphan Drug Designation to March Biosciences for T-Cell Lymphoma
By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T ...
Targeted Oncology1d
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
SEED receives FDA Rare Pediatric Disease, Orphan Drug designations for ST-01156
SEED Therapeutics announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease and Orphan Drug designations to ...
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- (March Bio), an emerging clinical stage biotechnology company committed to combating ...
Pharmabiz7h
March Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma
Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
In the Opportunity Research report, analyst Rob Goldman reviews clinical and preclinical data on OKYO's lead candidate, the Company's inherent first-mover opportunities in the industry, upcoming ...
Daily1d
Lupin, Avas unveil myotonia treatment NaMuscla in Italy
Mumbai: Global pharma major Lupin Limited and Avas Pharmaceuticals SRL have announced the launch of Lupin's orphan drug ...
Cure Today6d
FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS
The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...
Pharmabiz2d
Lupin and Avas launch NaMuscla in Italy to treat myotonia in adults with NDM disorders
Lupin and Avas launch NaMuscla in Italy to treat myotonia in adults with NDM disorders: Our Bureau, Mumbai Tuesday, January 28, 2025, 16:45 Hrs [IST] Global pharma major Lupin Lim ...
Lupin And Avas Launch Namuscla® In Italy
Lupin and Avas Launch NaMuscla® in Italy Enables expanded access to the only EU-approved <a target=_blank href=http ...
Lupin Ltd: Lupin and Avas Launch NaMuscla in Italy
Lupin and Avas Launch NaMuscla® in Italy Enables expanded access to the only EU-approved treatment for the myotonia symptoms in adults with non-dystrophic myotonic disorders Mumbai, Zug, January ...